Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
The latest in news from I-MAK experts.
For press inquiries, please contact simon@i-mak.org.
US business groups say verdict to impact pharma innovation in India (Business Standard)
The Indian Supreme Court Weighs In on Patent Evergreening (Health Affairs Blog)
The Hypocrisy of Novartis (Mumbai Mirror)
Only 3% of patents filed by MNC pharma firms under dispute: Study (Economic Times)
Novartis Loses Patent Appeal for Cancer Medication Glivec (Bloomberg BNA)
India’s Cancer-Drug Ruling Likely to Have Global Impact (Voice of America)
Novartis Loses Patent Bid: Lessons from India’s s(3d) Experience (IP Watch)
Voluntary License Scorecard
Update on I-MAK’s patent observations against Abbott Laboratories in Europe
Tahir Amin Speaks at the International AIDS Conference 2012